Arbutus Biopharma (NASDAQ:ABUS) has for some years owned the rights to a technology that can be used to deliver messenger RNA to a patient’s cells. Back in January 2019, Moderna (NASDAQ:MRNA), whose … [+1861 chars]
Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications – Motley Fool
